SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?
The nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney and the heart is increasingly being suggested to play a key role in mediating inflammation. In the kidney, NLRP3 activation was associated with the progression of diabetic kidney disease. In the heart, activatio...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/10/2294 |
| _version_ | 1797598750015750144 |
|---|---|
| author | Dimitris Kounatidis Natalia Vallianou Angelos Evangelopoulos Ioannis Vlahodimitris Eugenia Grivakou Evangelia Kotsi Krystalia Dimitriou Alexandros Skourtis Iordanis Mourouzis |
| author_facet | Dimitris Kounatidis Natalia Vallianou Angelos Evangelopoulos Ioannis Vlahodimitris Eugenia Grivakou Evangelia Kotsi Krystalia Dimitriou Alexandros Skourtis Iordanis Mourouzis |
| author_sort | Dimitris Kounatidis |
| collection | DOAJ |
| description | The nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney and the heart is increasingly being suggested to play a key role in mediating inflammation. In the kidney, NLRP3 activation was associated with the progression of diabetic kidney disease. In the heart, activation of the NLRP3 inflammasome was related to the enhanced release of interleukin-1β (IL-1β) and the subsequent induction of atherosclerosis and heart failure. Apart from their glucose-lowering effects, SGLT-2 inhibitors were documented to attenuate activation of the NLRP3, thus resulting in the constellation of an anti-inflammatory milieu. In this review, we focus on the interplay between SGLT-2 inhibitors and the inflammasome in the kidney, the heart and the neurons in the context of diabetes mellitus and its complications. |
| first_indexed | 2024-03-11T03:26:08Z |
| format | Article |
| id | doaj.art-1e88acca9a5f4b55bd51c14b072a1980 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T03:26:08Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-1e88acca9a5f4b55bd51c14b072a19802023-11-18T02:44:21ZengMDPI AGNutrients2072-66432023-05-011510229410.3390/nu15102294SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?Dimitris Kounatidis0Natalia Vallianou1Angelos Evangelopoulos2Ioannis Vlahodimitris3Eugenia Grivakou4Evangelia Kotsi5Krystalia Dimitriou6Alexandros Skourtis7Iordanis Mourouzis8Hippokration Hospital, 11572 Athens, GreeceEvangelismos General Hospital, 10676 Athens, GreeceRoche Diagnostics Hellas S.A., 15125 Athens, GreeceHippokration Hospital, 11572 Athens, GreeceHippokration Hospital, 11572 Athens, GreeceHippokration Hospital, 11572 Athens, GreeceHippokration Hospital, 11572 Athens, GreeceEvangelismos General Hospital, 10676 Athens, GreeceFaculty of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceThe nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney and the heart is increasingly being suggested to play a key role in mediating inflammation. In the kidney, NLRP3 activation was associated with the progression of diabetic kidney disease. In the heart, activation of the NLRP3 inflammasome was related to the enhanced release of interleukin-1β (IL-1β) and the subsequent induction of atherosclerosis and heart failure. Apart from their glucose-lowering effects, SGLT-2 inhibitors were documented to attenuate activation of the NLRP3, thus resulting in the constellation of an anti-inflammatory milieu. In this review, we focus on the interplay between SGLT-2 inhibitors and the inflammasome in the kidney, the heart and the neurons in the context of diabetes mellitus and its complications.https://www.mdpi.com/2072-6643/15/10/2294SGLT-2 inhibitorsinflammasomeNLRP3reno-protective effectscardioprotective effectsneuroprotective effects |
| spellingShingle | Dimitris Kounatidis Natalia Vallianou Angelos Evangelopoulos Ioannis Vlahodimitris Eugenia Grivakou Evangelia Kotsi Krystalia Dimitriou Alexandros Skourtis Iordanis Mourouzis SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? Nutrients SGLT-2 inhibitors inflammasome NLRP3 reno-protective effects cardioprotective effects neuroprotective effects |
| title | SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? |
| title_full | SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? |
| title_fullStr | SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? |
| title_full_unstemmed | SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? |
| title_short | SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? |
| title_sort | sglt 2 inhibitors and the inflammasome what s next in the 21st century |
| topic | SGLT-2 inhibitors inflammasome NLRP3 reno-protective effects cardioprotective effects neuroprotective effects |
| url | https://www.mdpi.com/2072-6643/15/10/2294 |
| work_keys_str_mv | AT dimitriskounatidis sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT nataliavallianou sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT angelosevangelopoulos sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT ioannisvlahodimitris sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT eugeniagrivakou sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT evangeliakotsi sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT krystaliadimitriou sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT alexandrosskourtis sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury AT iordanismourouzis sglt2inhibitorsandtheinflammasomewhatsnextinthe21stcentury |